207 related articles for article (PubMed ID: 38741108)
1. MDM2: current research status and prospects of tumor treatment.
Yao Y; Zhang Q; Li Z; Zhang H
Cancer Cell Int; 2024 May; 24(1):170. PubMed ID: 38741108
[TBL] [Abstract][Full Text] [Related]
2. Therapeutics Targeting p53-MDM2 Interaction to Induce Cancer Cell Death.
Koo N; Sharma AK; Narayan S
Int J Mol Sci; 2022 Apr; 23(9):. PubMed ID: 35563397
[TBL] [Abstract][Full Text] [Related]
3. Reactivation of p53 by inhibiting Mdm2 E3 ligase: a novel antitumor approach.
Di J; Zhang Y; Zheng J
Curr Cancer Drug Targets; 2011 Oct; 11(8):987-94. PubMed ID: 21762075
[TBL] [Abstract][Full Text] [Related]
4. Escape, or Vanish: Control the Fate of p53 through MDM2-Mediated Ubiquitination.
Wei J; Yang Y; Lu M; Xu L; Liu F; Yuan Z; Bao Q; Jiang Z; Xu X; Guo X; Zhang X; You Q; Sun H
Anticancer Agents Med Chem; 2015; 16(2):174-89. PubMed ID: 26343143
[TBL] [Abstract][Full Text] [Related]
5. Targeting p53-MDM2 interaction by small-molecule inhibitors: learning from MDM2 inhibitors in clinical trials.
Zhu H; Gao H; Ji Y; Zhou Q; Du Z; Tian L; Jiang Y; Yao K; Zhou Z
J Hematol Oncol; 2022 Jul; 15(1):91. PubMed ID: 35831864
[TBL] [Abstract][Full Text] [Related]
6. Reactivation of p53 by a specific MDM2 antagonist (MI-43) leads to p21-mediated cell cycle arrest and selective cell death in colon cancer.
Shangary S; Ding K; Qiu S; Nikolovska-Coleska Z; Bauer JA; Liu M; Wang G; Lu Y; McEachern D; Bernard D; Bradford CR; Carey TE; Wang S
Mol Cancer Ther; 2008 Jun; 7(6):1533-42. PubMed ID: 18566224
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic opportunities in cancer therapy: targeting the p53-MDM2/MDMX interactions.
Munisamy M; Mukherjee N; Thomas L; Pham AT; Shakeri A; Zhao Y; Kolesar J; Rao PPN; Rangnekar VM; Rao M
Am J Cancer Res; 2021; 11(12):5762-5781. PubMed ID: 35018225
[TBL] [Abstract][Full Text] [Related]
8. An integrated in silico screening strategy for identifying promising disruptors of p53-MDM2 interaction.
Sirous H; Chemi G; Campiani G; Brogi S
Comput Biol Chem; 2019 Dec; 83():107105. PubMed ID: 31473433
[TBL] [Abstract][Full Text] [Related]
9. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
10. The regulation of MDM2 by multisite phosphorylation--opportunities for molecular-based intervention to target tumours?
Meek DW; Hupp TR
Semin Cancer Biol; 2010 Feb; 20(1):19-28. PubMed ID: 19897041
[TBL] [Abstract][Full Text] [Related]
11. Targeting USP7-Mediated Deubiquitination of MDM2/MDMX-p53 Pathway for Cancer Therapy: Are We There Yet?
Qi SM; Cheng G; Cheng XD; Xu Z; Xu B; Zhang WD; Qin JJ
Front Cell Dev Biol; 2020; 8():233. PubMed ID: 32300595
[TBL] [Abstract][Full Text] [Related]
12. CK1alpha plays a central role in mediating MDM2 control of p53 and E2F-1 protein stability.
Huart AS; MacLaine NJ; Meek DW; Hupp TR
J Biol Chem; 2009 Nov; 284(47):32384-94. PubMed ID: 19759023
[TBL] [Abstract][Full Text] [Related]
13. A high-throughput screen measuring ubiquitination of p53 by human mdm2.
Murray MF; Jurewicz AJ; Martin JD; Ho TF; Zhang H; Johanson KO; Kirkpatrick RB; Ma J; Lor LA; Thrall SH; Schwartz B
J Biomol Screen; 2007 Dec; 12(8):1050-8. PubMed ID: 17989425
[TBL] [Abstract][Full Text] [Related]
14. Small molecule antagonists of the MDM2 oncoprotein as anticancer agents.
Buolamwini JK; Addo J; Kamath S; Patil S; Mason D; Ores M
Curr Cancer Drug Targets; 2005 Feb; 5(1):57-68. PubMed ID: 15720190
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of MDM2 Promotes Antitumor Responses in p53 Wild-Type Cancer Cells through Their Interaction with the Immune and Stromal Microenvironment.
Wang HQ; Mulford IJ; Sharp F; Liang J; Kurtulus S; Trabucco G; Quinn DS; Longmire TA; Patel N; Patil R; Shirley MD; Chen Y; Wang H; Ruddy DA; Fabre C; Williams JA; Hammerman PS; Mataraza J; Platzer B; Halilovic E
Cancer Res; 2021 Jun; 81(11):3079-3091. PubMed ID: 33504557
[TBL] [Abstract][Full Text] [Related]
16. Identification of antipsychotic drug fluspirilene as a potential p53-MDM2 inhibitor: a combined computational and experimental study.
Patil SP; Pacitti MF; Gilroy KS; Ruggiero JC; Griffin JD; Butera JJ; Notarfrancesco JM; Tran S; Stoddart JW
J Comput Aided Mol Des; 2015 Feb; 29(2):155-63. PubMed ID: 25377899
[TBL] [Abstract][Full Text] [Related]
17. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
[TBL] [Abstract][Full Text] [Related]
18. Discovery of RG7112: A Small-Molecule MDM2 Inhibitor in Clinical Development.
Vu B; Wovkulich P; Pizzolato G; Lovey A; Ding Q; Jiang N; Liu JJ; Zhao C; Glenn K; Wen Y; Tovar C; Packman K; Vassilev L; Graves B
ACS Med Chem Lett; 2013 May; 4(5):466-9. PubMed ID: 24900694
[TBL] [Abstract][Full Text] [Related]
19. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
20. Targeting MDM2-p53 Axis through Drug Repurposing for Cancer Therapy: A Multidisciplinary Approach.
Ghafoor NA; Yildiz A
ACS Omega; 2023 Sep; 8(38):34583-34596. PubMed ID: 37779953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]